HRAS

(redirected from K-RAS)

HRAS

A gene on chromosome 11p15.5 belonging to the Ras oncogene family, the protein products of which bind GTP and GDP, have intrinsic GTPase activity, and play key roles in signal transduction. HRAS cycles between de- and re-palmitoylation, a reaction that regulates its rapid exchange between the plasma membrane and the Golgi apparatus.

Molecular pathology
Defects in HRAS are associated with an increased risk of bladder cancer, Hürthle cell carcinoma of thyroid, and oral squamous cell carcinoma. HRAS mutations cause faciocutaneoskeletal syndrome and congenital myopathy with excess of muscle spindles—a variant of Costello syndrome.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
Whereas H-RAS mutation was detected in as much as 35% of Indian oral cancer specimens [27] and has been associated with betel nut chewing, K-RAS mutation prevalences vary considerably [23, 27].
Numerous studies have shown that mutations of the K-ras and TP53 genes are common in colorectal adenocarcinomas [18, 19].
Pancreatic cancer is characterized by mutation of K-ras in about 90-95 % of cases where K-ras becomes constitutively activated and promotes cellular proliferation via the mitogen activated protein kinase (MAPK or Erk) pathway (Hruban et al 2001, Hezel et al 2006).
"In addition to this study, we are enrolling patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumors in a U.S.
* K-RAS gene testing for guiding drug choice in metastatic colorectal cancer.
In many bowel cancers, K-Ras is faulty and stuck in the "on" position, fuelling tumour growth.
CTBE cells showed global DNA hypomethylation and c-myc and k-ras overexpression, typical in aggressive breast cancers.
NSCL cancer cells often harbor mutations in a gene called K-RAS. Patients with such K-RAS mutations typically are more resistant to treatment with radiation and have a poor prognosis.
EUROPAC screening includes serum glucose and the CA 19.9 measurement, CT, EUS and ERCP to analyse p16, K-RAS and p53 oncogenes, in pancreatic juice.
The aspirate was subjected to a series of tests, one of which was a molecular diagnostic assay for k-ras mutations.